No introductions necessary: A TCR upstart with deep-pocket backers partners with one of the new players in the hot gene editing field
When Affini-T arrived on the scene a few weeks ago, it had most of the essential elements needed by any biotech upstart.
There were high-profile scientific founders, Phil Greenberg, Tom Schmitt and Aude Chapuis, at the Fred Hutch. A motherlode of cash from ambitious investors like Vida Ventures and Leaps by Bayer. And the building blocks of new drugs to go after oncogenic drivers like KRAS and p53.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.